<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1024">
  <stage>Registered</stage>
  <submitdate>24/01/2006</submitdate>
  <approvaldate>27/01/2006</approvaldate>
  <actrnumber>ACTRN12606000040561</actrnumber>
  <trial_identification>
    <studytitle>The safety and efficacy of Cpn10 in psoriasis</studytitle>
    <scientifictitle>A single centre, double blind, parallel group, three arm, Phase IIa clinical trial designed to assess the efficacy and safety of Cpn10 administered as twice weekly intravenous injections in subjects with plaque psoriasis.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CBio Ltd: CBIO 2005-01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Psoriasis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>
Cpn10 7.5mg twice per week
Cpn10 10mg twice per week 
given as intravenous injections over 12 weeks</interventions>
    <comparator>Cpn10 5mg twice per week</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy will be measured by a 75 % improvement in disease extent and severity, as measured by the PASI score (PASI-75 response).</outcome>
      <timepoint>After 12 weeks.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. PASI 75 response </outcome>
      <timepoint>Anytime up to 12 weeks + 4 weeks follow up.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. PASI 50 response</outcome>
      <timepoint>Anytime up to 12 weeks + 4 weeks follow up.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. PASI 90 response</outcome>
      <timepoint>At week 12 or anytime.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. Physician Global Assessment</outcome>
      <timepoint>Anytime up to 12 weeks + 4 weeks follow up.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5. Mean % PASI reduction</outcome>
      <timepoint>Anytime up to 12 weeks + 4 weeks follow up.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6. Cytokine production by PBMC stimulation in vitro</outcome>
      <timepoint>Anytime up to 8 weeks.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Have been diagnosed with plaque psoriasis for at least 6 months. 2. Have plaque psoriasis covering &gt; 10 % body surface area (BSA). 3. Have a PASI score of &gt; 12 at the screening visit. 4. Have a Physicians Global Assessment (PGA) Score of at least moderate at the screening visit. 5. Have psoriasis that is not controlled by current therapies. 6. Weigh less than 120 kg. 7. Sexually active women of child bearing potential must agree to use a medically reliable method of preventing conception for the duration of the study, unless surgically sterile or post menopausal.  Sexually active men whose partners are of childbearing potential must agree to use a medically reliable method of preventing conception for the duration of the study, unless surgically sterile. 8. Be willing to hold sun exposure reasonably constant and to avoid use of tanning booths during the study. Narrowband UVB (NBUVB) treatment for psoriasis is permitted prior to and during the course of this study. 9. Have provided written informed consent to participate in the trial.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Have guttate, erythrodermic or pustular psoriasis as the sole or predominant form of psoriasis.2. History of allergic or anaphylactic reactions to Cpn10.3. Have a clinically significant psoriasis flare during screening or at the time of enrolment.4. Have a history of or ongoing bacterial, viral, fungal or atypical mycobacterial infection.5. Have a history of opportunistic infections (e.g. systemic fungal infections, parasites) within the preceding 6 months.6. Have a seropositive test to HIV, Hepatitis B or Hepatitis C at screening.7. Female who is lactating or pregnant (confirmed by a positive serum ?-HCG pregnancy test at screening).8. Subjects with the following laboratory test results at screening:(a) White blood cell (WBC) count &lt;4000/L(b) Aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase levels greater than 3 times the upper limit of normal range for the laboratory conducting the test.(c) Serum creatinine &gt; 2 times the upper limit of normal range for the laboratory conducting the test.9. Have a history of active tuberculosis confirmed by a chest X-ray and Quantiferon TB gold testing at screening10. Have been diagnosed with a malignancy or have a history of malignancy within the last 5 years.  Subjects with fully excised basal or squamous cell carcinomas may be enrolled.11. Have a diagnosis of hepatic cirrhosis, regardless of the cause or severity.12. Have been admitted to hospital for cardiac disease, stroke or pulmonary disease within the last 12 months13. Have a history of substance abuse within the last 5 years.14. Have a medical condition that in the opinion of the investigator would jeopardise the subjects safety following exposure to the study drug.15. Have received treatment with the following medications:(a) Immunosuppressive drugs within 28 days prior to study day 0.(b) Prior treatment with the following anti-TNF-alpha agents: infliximab, etanercept or adalumumab(c) Live or killed virus or bacteria vaccines within 14 days of study day 0(d) Other vaccines or allergy desensitisation therapies within 14 days of study day 0(e) Other experimental drugs or treatments within 28 days or 5 half-lives (whichever is longer) prior to study day 0(f) Beta-blockers, ACE inhibitors, interferons, quinidine, antimalarial drugs or lithium.  If clinically indicated these medications are allowed but the dosage must be held constant from screening and throughout the trial period.16. Deemed by the investigator to be uncooperative or unsuitable for inclusion into this trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sequential codes</concealment>
    <sequence>Blocked random sequence generated in EXCEL.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/07/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>CBio Limited</primarysponsorname>
    <primarysponsoraddress>85 Brandl St
Eight Mile Plains  QLD 4113</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>CBio Limited</fundingname>
      <fundingaddress>85 Brandl St
Eight Mile Plains QLD 4113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Safety and effectiveness of Cpn10 in patients with moderate to severe psoriasis.  Three doses of Cpn10 are being trialed.  The study personnel performing the assessments, the sponsor and the patient  are blinded to which of the three doses are administered.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Emeritus Research</ethicname>
      <ethicaddress>291 Wattletree Rd, Malvern VIC 3144</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Dennis Feeney</name>
      <address>CBio Limited
85 Brandl St
Eight Mile Plains QLD 4113</address>
      <phone>+61 7 38414844</phone>
      <fax>+61 7 38418189</fax>
      <email>dennis.feeney@cbio.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Bronwyn Williams</name>
      <address>CBio Limited
85 Brandl St
Eight Mile Plains QLD 4113</address>
      <phone>+61 7 38414844</phone>
      <fax>+61 7 38418189</fax>
      <email>bronwyn.williams@cbio.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>